Young Joseph R 4

4 · Vera Therapeutics, Inc. · Filed Feb 6, 2026

AI-generated summary of this filing

Updated Feb 7, 2026

Vera Therapeutics SVP Joseph R. Young Receives RSU & Option Awards

What Happened

Joseph R. Young, Senior Vice President, Finance and Chief Accounting Officer of Vera Therapeutics (VERA), received equity awards on February 4, 2026: 10,000 restricted stock units (RSUs) and 20,000 derivative securities (an option award). Both awards were granted at $0.00 (i.e., no cash purchase price). These are compensation grants, not open-market purchases or sales.

Key Details

Transaction date: 2026-02-04; Form 4 filed 2026-02-06 (timely — within the standard 2 business days).
Awards: 10,000 RSUs (acquired at $0.00) and 20,000 derivative/share-equivalent award (acquired at $0.00).
Post-transaction holdings: Not specified in the filing.
Vesting / footnotes:
- RSUs (10,000): Vest one-fourth on each of Feb 20, 2027, 2028, 2029 and 2030, subject to continuous service. (Footnote F1)
- Derivative award (20,000): Vests 1/48th on March 4, 2026 and 1/48th monthly thereafter (subject to continuous service), per the filing (Footnote F2).
Transaction code: A = Award/Grant.
No indications of tax-withholding sale, 10b5-1 plan, or that shares were immediately sold.

Context

These grants are routine equity compensation for an executive and do not represent an open-market buy or sell. Such awards are intended as long-term incentive/retention and vest over multiple years; they should not be read as a direct market-timing signal. The derivative award is an option-like grant with monthly vesting; RSUs convert to shares only as they vest.

Form 4

Period: 2026-02-04

SVP, FINANCE, CHIEF ACCT OFFCR

Transactions

Award
Class A Common Stock
[F1]
2026-02-04+10,000→ 67,839 total
Award
Stock Option (right to buy)
[F2]
2026-02-04+20,000→ 20,000 total
Exercise: $42.74Exp: 2036-02-03→ Class A Common Stock (20,000 underlying)

Footnotes (2)

[F1]Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date.
[F2]1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.

Signature

/s/ Joseph R. Young|2026-02-06

1 file